Health Economics›Non-small cell lung cancer›All lines of therapy

All lines of therapy

Non-small cell lung cancer · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Crizotinib monotherapy Variant #01	ALK	R 119 525	28d	~11.1 mo	—	~13	~R 1 553 824 PFS proxy · indirect	12
Osimertinib monotherapy Variant #01	EGFR	R 77 777	28d	~16.6 mo	~38.1 mo	~19	~R 1 477 762 PFS proxy · indirect	15
Ceritinib monotherapy Variant #01	ALK	R 35 198	28d	~11.0 mo	—	~12	~R 422 372 PFS proxy · indirect	2
Afatinib monotherapy Variant #01	EGFR	R 34 727	28d	~11.0 mo	~10.8 mo	~12	~R 416 729 PFS proxy · indirect	5
Cisplatin, Gefitinib, Pemetrexed Variant #01	EGFR	R 9 643	28d	—	~35.0 mo	—	—	1
Gefitinib, Nedaplatin, Pemetrexed Variant #01 Partial	EGFR	R 9 268	28d	—	~35.0 mo	—	—	1
Gefitinib monotherapy Variant #01	EGFR	R 8 556	28d	~9.7 mo	~17.0 mo	~11	~R 94 111 PFS proxy · indirect	27
Cisplatin and Vinorelbine (CVb) Variant #11	—	R 4 117	42d	—	~10.0 mo	—	—	10
Dexamethasone monotherapy Variant #11	—	R 1 389	35d	—	—	—	—	—
Alectinib monotherapy Variant #01	ALK	R 108	28d	~27.0 mo	—	~30	~R 3 229 PFS proxy · indirect	7
Whole brain irradiation N/A - radiation Partial	—	—	21d	—	—	—	—	1
Icotinib monotherapy Variant #01 Partial	EGFR	—	28d	~11.2 mo	—	~13	—	5
Teniposide monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
Teniposide and WBRT Variant #01 Partial	—	—	21d	—	—	—	—	—
Dexamethasone and WBRT Variant #01 Partial	—	—	—	—	—	—	—	—

15 of 15 regimens shown